LMR Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.79M Sell
5,000
-3,100
-38% -$3.66M 0.02% 626
2026
Q2
$9.7M Sell
8,100
-172,200
-96% -$176M 0.04% 429
2026
Q1
$166M Buy
+180,300
New +$183M 0.37% 24
2025
Q3
– Sell
-96,700
Closed -$75.4M – 1566
2025
Q2
$75.4M Hold
96,700
– – 0.54% 31
2025
Q1
$79.9M Buy
+96,700
New +$80.5M 0.75% 16
2024
Q1
– Sell
-47,000
Closed -$27.4M – 1245
2023
Q4
$27.4M Buy
47,000
+22,100
+89% +$12.9M 0.31% 71
2023
Q3
$13.4M Sell
24,900
-155,900
-86% -$80.3M 0.15% 154
2023
Q2
$84.8M Buy
+180,800
New +$75.8M 0.94% 12

Other funds holding LLY

LMR Partners's LLY Position: Q3 2026 in Review

LMR Partners reduced its Eli Lilly (LLY) stake by 83% in Q3 2026, selling an estimated $3.3M and leaving 590 shares worth $683K. The position accounts for ﹤0.01% of the portfolio, ranked #1166.

LMR Partners first reported a position in LLY in Q2 2015 and has held it in 25 quarters since. The position peaked at $86M in Q1 2026. 4,616 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • LMR Partners held 590 shares of Eli Lilly worth $683K as of Q3 2026.
  • LMR Partners sold 2,800 Eli Lilly shares in Q3 2026, an estimated $3.3M.
  • Eli Lilly made up ﹤0.01% of LMR Partners's portfolio in Q3 2026, its #1166 holding.
  • LMR Partners first reported a position in Eli Lilly in Q2 2015 and has held it in 25 quarters since.
  • LMR Partners's Eli Lilly position peaked at $86M in Q1 2026.
  • 4,616 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on LMR Partners's 13F filing for Q3 2026, filed 16 Nov 2026.